ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO424

Non-Steroidal Mineralocorticoid Receptor Antagonists (MRAs)-Finerenone Ameliorates Mitochondrial Dysfunction via PI3K/Akt Signaling Pathway in Diabetic Tubulopathy

Session Information

Category: Diabetic Kidney Disease

  • 701 Diabetic Kidney Disease: Basic


  • Wang, Pei, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

Diabetic tubulopathy (DT) is gradually valued and elucidated as same as glomerular pathology in the pathophysiological perturbations of diabetic kidney disease (DKD). The mitochondria-centric view of DT is emerging as a vital pathological factor in metabolic diseases including DKD. Finerenone (FIN), a novel non-steroidal MRAs, attenuates proteinuria and fibrosis in tubules in DM, but these precise pathomechanisms remain unclear.


We investigated the role of mineralocorticoid receptor (MR) activation in perturbation of mitochondrial function via PI3K/Akt signaling pathway, including mitochondrial dynamics and mitophagy, under a DM state or hyperglycemia ambience.


In vivo, the molecules were examined in kidneys of DM and FIN treatment mice as well. Notably, FIN administration partially attenuated mitochondrial fragmentation, oxidative stress, and apoptosis and restored mitophagy via PI3K/Akt signaling pathway both in HK-2 cells subjected to HG ambience and tubular cells of DM mice.


These results suggest a novel mechanism linking MR activation to mitochondrial dysfunction via PI3K/Akt signaling pathway during tubular injury in the pathogenesis of DKD and it provides evidence support for FIN as a agent for the treatment of DKD.